- Home
- MGRX vs NXL Comparison
MGRX vs NXL Comparison
Compare MGRX & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGRX | NXL |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 7.5M |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | MGRX | NXL |
|---|---|---|
| Price | $0.26 | $2.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 522.9K | ★ 2.0M |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.17 | 39.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $456,021.00 | $301,647.00 |
| Revenue This Year | N/A | $14.37 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 78.78 |
| 52 Week Low | $0.26 | $0.22 |
| 52 Week High | $2.50 | $99.00 |
Technical Indicators
Market Signals| Indicator | MGRX | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 30.21 | 31.26 |
| Support Level | N/A | $0.22 |
| Resistance Level | $0.49 | $5.36 |
| Average True Range (ATR) | 0.04 | 0.50 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 2.60 | 2.06 |
Price Performance
Historical ComparisonAbout MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.